Bayn Europe AB, an independent developer of sugar replacement solutions, has had a record order intake in February. The value of the order intake is estimated at about 1,2 MSEK.
“The order intake for Bayn’s sugar replacement solution EUREBA®, the sales of which took off last summer, continues to increase. During the month of February Bayn has taken up orders to a value of about 1,2 MSEK. At the same time enquiries have increased, so we have reason to expect that the trend will be maintained”, says Patrik Edström, CEO at Bayn Europe.
The increase in sales is partly due to results from the processing of existing customers, and the effects of the company’s presence at the Health Ingredients Europe fair in Frankfurt last November.
“Further to our successful direct sales our distributors have also been very successful in selling EUREBA®, and also NAVIA® for which we have signed contracts with manufacturers in the EU market”, says Mats Källqvist, SVP Market & Sales at Bayn Europe.
For more information:
Patrik Edström, CEO, Bayn Europe AB, e-mail email@example.com
Bayn is listed on Nasdaq Stockholm, First North, under the short name BAYN. Mangold Fondkommission AB is Bayn’s certified adviser. Telephone +46-8-5030 1550, e-mail CA@mangold.se.
This information is such information which Bayn Europe AB is required to disclose according to EU’s Market Abuse Regulation. The information was provided by the above contact person for publication on 4 mars 2019 kl. 15.40 CET.